Trial Profile
A Multicenter, Randomized, Open-label, Active-drug Controlled Study to evaluate efficacy and safety of Sitafloxacin in patients with Community-acquired Pneumonia in China
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2015
Price :
$35
*
At a glance
- Drugs Sitafloxacin (Primary) ; Moxifloxacin
- Indications Community-acquired pneumonia
- Focus Adverse reactions; Therapeutic Use
- 28 Oct 2015 New trial record